Travere Therapeutics’ Filspari (sparsentan) cleared a new regulatory milestone, becoming the first FDA-approved treatment for focal segmental glomerulosclerosis (FSGS). The approval expands use beyond the drug’s earlier label, where it already won full approval for IgA nephropathy. Regulatory documents and subsequent reporting indicate the label was built on proteinuria as a surrogate endpoint, with the update covering children and adults aged 8 and older who do not have nephrotic syndrome. The FSGS clearance follows Travere’s earlier accelerated approvals in kidney disease and marks a step-change in commercial opportunity. The approval also ends a lengthy regulatory journey that began with clinical results and progressed through multiple decision points, positioning sparsentan to compete in an area with limited fully approved options.